<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940780</url>
  </required_header>
  <id_info>
    <org_study_id>INTEGR.ONCOL.REGIST-2021</org_study_id>
    <nct_id>NCT04940780</nct_id>
  </id_info>
  <brief_title>Integrative Oncology for Patient Symptoms</brief_title>
  <official_title>Examining the Impact of an Integrative Oncology Program on Patient Symptoms and Quality of Life: a Prospective Pragmatic Registry Protocol Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of complementary and integrative medicine (CIM) among oncology patients is&#xD;
      widespread, with a large body of research-based evidence supporting the ability of these&#xD;
      therapies to alleviate symptoms related to cancer and its treatment. Organizations such as&#xD;
      the American Society for Clinical Oncology and the European Society for Medical Oncology have&#xD;
      included CIM modalities in their treatment guidelines, and many of today's leading cancer&#xD;
      centers include CIM in their supportive care service. The proposed study will prospectively&#xD;
      examine the impact of a CIM treatment program on the symptom burden, quality of life and&#xD;
      function of patients undergoing active oncology treatment.&#xD;
&#xD;
      A total of 750 patients will undergo an integrative oncologist (IP) consultation followed by&#xD;
      a series of 8 CIM treatments consisting of either acupuncture or touch-related therapies&#xD;
      (reflexology, Shiatsu, Tuina, etc.) with the goal of relieving their symptoms. Patients will&#xD;
      be allocated to one of the two study treatment arms: the &quot;Patient-Preference Arm&quot;, for&#xD;
      patients who specify their preference for either acupuncture or touch therapy; and the&#xD;
      &quot;Randomized Treatment Arm&quot;, for those with no preference, to be randomly allocated to either&#xD;
      the acupuncture or touch-therapy subgroup. Patients will be asked to complete the following&#xD;
      study questionnaires before and after the treatment regimen: the European Organization for&#xD;
      Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30); the Edmonton&#xD;
      Symptom Assessment System (ESAS); and the Measure Yourself Concerns and Wellbeing (MYCAW)&#xD;
      tool. The primary study outcome will be the change in EORTC Global Health-Status / Quality of&#xD;
      Life scores, from pre- to post-treatment. Secondary study outcomes will include EORTC QLQ-C30&#xD;
      functional and symptom scales, single items assessing additional symptoms commonly reported&#xD;
      by cancer patients, and perceived financial impact of the disease; ESAS severity scores for&#xD;
      10 quality-of life related items; and MYCAW severity scores for the 2 most significant&#xD;
      symptoms, as well as post-treatment narratives. Other secondary outcomes to be assessed&#xD;
      include the safety of the study treatments (adverse effects); adherence to conventional&#xD;
      treatment regimen; and narratives from the patient's informal caregiver (spouse,&#xD;
      parent/child, sibling, friend, etc.).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patient-preference, pragmatic methodology</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EORTC QLQ-C30 global health status / QoL scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline to the end of the 8-week integrative treatment program</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 global health status / QoL scale</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline and 8-week assessment to 16 week follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 - additional outcomes</measure>
    <time_frame>From baseline to 8- (end of treatment program) and 16-week (post-program) assessment</time_frame>
    <description>Change in functional and symptom scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESAS symptom severity scores</measure>
    <time_frame>From baseline to 8- (end of treatment program) and 16-week (post-program) assessment</time_frame>
    <description>Change in severity scores for 10 quality-of life related items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MYCAW symptom severity scores</measure>
    <time_frame>From baseline to 8- (end of treatment program) and 16-week (post-program) assessment</time_frame>
    <description>Change in severity scores for the 2 most significant symptoms, as well as post-treatment narratives</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse effects</measure>
    <time_frame>At the end of the series of 8 weekly CIM treatment sessions (≤ 2 weeks after the last treatment session); after 16 weeks from baseline.</time_frame>
    <description>Any reported adverse events taking place during the study period which are considered to have possibly/probably resulted from the CIM intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to conventional oncology treatment regimen</measure>
    <time_frame>At 16 weeks from baseline.</time_frame>
    <description>Adherence to oncology treatment to be measured using the Relative Dose Intensity (RDI) calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver expectations</measure>
    <time_frame>At baseline</time_frame>
    <description>Narratives from the patient's informal caregiver (spouse, parent/child, sibling, friend, etc.).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Oncologic Complications</condition>
  <condition>Symptoms and Signs</condition>
  <arm_group>
    <arm_group_label>Patient Preference Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who specify their preference for either acupuncture or touch therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with no preference, to be randomly allocated to either the acupuncture or touch-therapy subgroup</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms</description>
    <arm_group_label>Patient Preference Arm</arm_group_label>
    <arm_group_label>Randomized Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Touch Therapies</intervention_name>
    <description>Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch</description>
    <arm_group_label>Patient Preference Arm</arm_group_label>
    <arm_group_label>Randomized Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  undergoing active oncology treatment&#xD;
&#xD;
          -  fully understand the study plan&#xD;
&#xD;
          -  agree to sign the study informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not fulfilling all of the study criteria&#xD;
&#xD;
          -  not interested in attending all 8 weekly CIM treatments sessions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Noah Samuels, M.D.</last_name>
    <phone>972-26666395</phone>
    <email>noahs@szmc.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Oncology, Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>7791031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Noah Samuels, M.D.</last_name>
      <phone>026666395</phone>
      <email>noahs@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Nathan Cherny, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Samuels N, Oberbaum M, Ben-Arye E. Expectations of Patients and Their Informal Caregivers from an Integrative Oncology Consultation. Integr Cancer Ther. 2021 Jan-Dec;20:1534735421990080. doi: 10.1177/1534735421990080.</citation>
    <PMID>33588610</PMID>
  </reference>
  <reference>
    <citation>Samuels N, Ben-Arye E. Integrative Approaches to Chemotherapy-Induced Peripheral Neuropathy. Curr Oncol Rep. 2020 Feb 11;22(3):23. doi: 10.1007/s11912-020-0891-2. Review.</citation>
    <PMID>32048067</PMID>
  </reference>
  <reference>
    <citation>Ben-Arye E, Dahly H, Keshet Y, Dagash J, Samuels N. Providing integrative care in the pre-chemotherapy setting: a pragmatic controlled patient-centered trial with implications for supportive cancer care. J Cancer Res Clin Oncol. 2018 Sep;144(9):1825-1833. doi: 10.1007/s00432-018-2700-y. Epub 2018 Jul 6.</citation>
    <PMID>29980837</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaare Zedek Medical Center</investigator_affiliation>
    <investigator_full_name>Noah Samuels</investigator_full_name>
    <investigator_title>Director, Center for Integrative Complementary Medicine</investigator_title>
  </responsible_party>
  <keyword>Integrative medicine</keyword>
  <keyword>Integrative oncology</keyword>
  <keyword>Acupuncture</keyword>
  <keyword>Touch therapy</keyword>
  <keyword>Wellbeing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

